Latest Revenue Outlook News

Electro Optic Systems reported a 27% revenue drop to $128.5 million in FY2025 but posted a net profit of $18.6 million, boosted by the sale of EM Solutions. The company strengthened its position with key contract wins and acquisitions, including the UK-based Interceptor business and a conditional deal for MARSS.

HighCom Limited has announced a $7 million capital raise alongside a $1 million Share Purchase Plan to support working capital and product innovation, aiming for a strong revenue rebound and profitability in the second half of FY26.

GQG Partners reported a rise in Funds Under Management to USD 165.7 billion as of January 2026, buoyed by strong investment performance despite notable net outflows during the month.

Jcurve Solutions has reported a robust Q2FY26 with a significant profit turnaround and a confident revenue outlook for FY26, driven by strong sales and recurring revenue growth.

GCM Corporation is advancing its commercialisation strategy with multiple prototypes across key global markets and sectors, aiming for revenue in the first half of 2026.

TradeWindow reports solid growth in recurring revenue and average revenue per customer but lowers its FY26 trading revenue guidance due to softer transactional volumes in Q3.

Papyrus Australia has taken a significant step towards commercialisation with a $4.2 million supply contract and the near completion of its Adelaide Rapid Prototyping and R&D Facility.

Vitasora Health Limited reported a significant 22% increase in daily clinical billing productivity for the December 2025 quarter, alongside a 17% rise in operating revenue. With new CMS reimbursement policies now in effect, the company anticipates a further 10–20% revenue uplift in 2026.

Dubber Corporation Limited has signed a significant five-year contract with a major North American communications provider, while trimming costs and targeting operating cashflow breakeven in FY26.

Frontier Energy has unveiled a significant uplift in revenue projections for Stage One of its Waroona Renewable Energy Project, enhancing its debt financing prospects and shareholder returns.

Neuren Pharmaceuticals has affirmed the material impact of Acadia’s projection that DAYBUE global net sales could reach approximately US$700 million by 2028, underpinning its royalty revenue outlook.

Amaero Ltd has lowered its FY2026 revenue guidance due to delayed U.S. government contracts but reports strong contracted revenue and a robust cash position heading into 2026.